Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Stock Information for Kidpik Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kidpik Corp.

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders
UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.